Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 22 · below the Ichimoku cloud · RSI 37 · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in CVSI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CVSI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for CVSI.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -33.3 | 125.0 | -66.7 | 0.0 | 0.0 | -33.3 | 0.0 | 0.0 | -50.0 | 0.0 | −83.3% | ||
| 2025 | 33.3 | -25.0 | 0.0 | 0.0 | 0.0 | 33.3 | 0.0 | 0.0 | 0.0 | -25.0 | 0.0 | 100.0 | +100.0% |
| 2024 | 0.0 | -25.0 | 33.3 | 25.0 | 40.0 | -14.3 | -16.7 | 0.0 | 0.0 | -20.0 | 0.0 | -25.0 | −25.0% |
| 2023 | 33.3 | 25.0 | -20.0 | 25.0 | 0.0 | -20.0 | 0.0 | 0.0 | 25.0 | -20.0 | 0.0 | 0.0 | +33.3% |
| 2022 | 25.0 | -20.0 | 41.7 | -47.1 | -55.6 | 0.0 | -25.0 | 66.7 | -20.0 | 0.0 | 0.0 | -25.0 | −75.0% |
| 2021 | 12.8 | 22.6 | -29.2 | -8.7 | -2.4 | -7.3 | -13.2 | -9.1 | -20.0 | -12.5 | -14.3 | -33.3 | −74.5% |
| 2020 | -6.2 | -24.2 | -15.9 | -13.8 | 78.0 | -30.3 | -3.2 | -5.0 | -7.0 | -13.2 | 37.0 | -25.4 | −51.5% |
| 2019 | 29.9 | -14.3 | 23.3 | -11.0 | -16.7 | -7.3 | -1.5 | -16.5 | -48.7 | 20.3 | -41.5 | -19.8 | −77.5% |
| 2018 | -33.9 | -2.4 | 25.0 | 60.0 | 91.2 | 8.5 | 88.0 | 38.8 | 11.5 | 3.5 | 0.2 | -14.0 | +595.2% |
| 2017 | 11.6 | -12.5 | -4.8 | -20.0 | -9.4 | -3.4 | -7.1 | -11.5 | 30.4 | -23.3 | 0.0 | 169.6 | +44.2% |
| 2016 | -16.7 | -5.0 | 105.3 | 23.1 | -4.2 | -8.7 | -14.3 | -30.6 | 32.0 | 181.8 | -68.8 | 48.3 | +79.2% |
| 2015 | 28.0 | -8.6 | -13.4 | -13.0 | -27.9 | -18.7 | -9.0 | -15.3 | -27.7 | 35.3 | -38.0 | -57.9 | −89.8% |
| 2014 | 145.3 | 110.4 | -74.1 | -49.3 | -11.6 | -24.4 | -54.3 | -47.5 | -9.0 | 13.8 | -10.3 | -18.1 | −91.7% |
| 2013 | 114.3 | 33.3 | -45.0 | 25.0 | 1.8 | 42.9 | 95.0 | -20.5 | -51.9 | 91.3 | +307.1% |
No analyst coverage for this instrument.
CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.